ZIOPHARM Oncology, Inc.

Click to receive news alerts

A Phase II multicenter, parallel group, randomized study of palIfosfamide tris plus doxorubicin versus doxorubiCin in subjects with unresectAble or metastatic Soft tissue SarcOma

Now Enrolling: ZIOPHARM Oncology, Inc. has launched its global Phase 2 randomized controlled trial of palifosfamide in subjects with unresectable or metastatic soft-tissue sarcoma. (PICASSO).
Click here to learn more.

November 11, 2009

ZIOPHARM Reports Third Quarter Financial Results and Updated Clinical Progress More

November 9, 2009

ZIOPHARM to Host Analyst & Institutional Investor Meeting on November 19, 2009 More

Media Coverage

Businessweek article
July 23, 2007 issue More

Businessweek article
May 5, 2008 issue More

Forbes.com article
May 9, 2008 issue More

ZIO-101 listed as 100 Great Investigational Drugs by R&D Directions More

ZIO-201 listed as 100 Great Investigational Drugs by R&D Directions More

Webcast

Events and Presentations

ZIOPHARM Analyst & Institutional Investor Meeting
November 19, 2009
Click Here for More Information

ZIOPHARM Oncology, Inc. at the Merriman 6th Annual Investor Summit 2009
November 10, 2009
Click Here for More Information

ZIOPHARM Oncology, Inc. 8th Annual BIO Investor Forum
October 29, 2009
Click Here for More Information

ZIOPHARM Oncology, Inc. at the 4th Annual JMP Healthcare Focus Conference
October 5, 2009
Click Here for More Information

ZIOPHARM Oncology, Inc. at the Rodman & Renshaw 11th Annual Healthcare Conference
September 10, 2009
Click Here for More Information